Angiogenesis and hypertension: The dual role of anti-hypertensive and anti-angiogenic therapies

Current Vascular Pharmacology

Volumn 10, Issue 4, 2012, Pages 479-493

  Ferroni, Patrizia ^a   Della Morte, David ^a,b   Palmirotta, Raffaele ^a   Rundek, Tatjana ^b   Guadagni, Fiorella ^a   Roselli, Mario ^c  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Angiogenesis; Antihypertensive drugs; Bevacizumab; Endothelium; Essential hypertension; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FLUOROPYRIMIDINE; FLUOROURACIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRINOTECAN; LOSARTAN; NEBIVOLOL; NIFEDIPINE; PACLITAXEL; PERINDOPRIL; PRAZOSIN; PROPRANOLOL; QUINAPRILAT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEREDITY; HOMEOSTASIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861662862     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112800812836     Document Type: Review

References (156)

1. Brener SJ. Insights into the pathophysiology of ST-elevation myocardial infarction. Am Heart J 2006; 151: S4-10.
2. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-95.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-60.
4. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
5. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
6. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
7. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
8. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224-32.
9. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
10. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
11. Steg PG, James S, Harrington RA, et al. Ticagrelor vs. clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-41.
12. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-31.
13. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-7.
14. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR, Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009; 53: 2019-27.
15. van der Meijden PE, Feijge MA, Giesen PL, Huijberts M, van Raak LP, Heemskerk JW. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005; 93: 1128-36.
16. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-8.
17. Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008; 29: 1504-9.
18. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
19. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-16.
20. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-30.
21. Parodi G, Antoniucci D, Nikolsky E, et al. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 2010; 3: 796-802.
22. Cortese B, Micheli A, Picchi A, et al. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. Coron Artery Dis 2009; 20: 348-53.
23. Cortese B, Picchi A, Micheli A, et al. Comparison of prolonged bivalirudin infusion vs. intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris. Am J Cardiol 2009; 104: 1063-8.
24. Cortese B, Limbruno U, Severi S, De Matteis S, Diehl L, Pitì A. Effect of prolonged Bivalirudin infusion on ST-segment resolution following primary percutaneous coronary intervention (from the PROBI VIRI 2 study). Am J Cardiol 2011; 108: 1220-4. focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997; 272: 15442-51.
25. Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000; 275: 10661-72.
26. Qi JH, Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res 2001; 263: 173-82.
27. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997; 15: 2169-77.
28. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001; 276: 3222-30.
29. Goligorsky MS, Abedi H, Noiri E, et al. Nitric oxide modulation of focal adhesions in endothelial cells. Am J Physiol 1999; 276: C1271-81.
30. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGFinduced endothelial cell migration. FEBS Lett 2000; 477: 258-62.
31. Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. J Biol Chem 1997; 272: 1747-52.
32. Papapetropoulos A, Garcia-Gardena G, Madri J, Sessa W. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-9.
33. Ferroni P, Formica V, Roselli M, Guadagni F. Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs. Curr Vasc Pharmacol 2010; 8: 102-13.
34. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703.
35. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol 1998; 274: H1054-8.
36. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265: H586-92.
37. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997; 420: 28-32.
38. Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and-2 heterodimer. J Biol Chem 2005; 280: 9904-12.
39. Eppler SM, Combs DL, Henry TD, et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002; 72: 20-32.
40. Li B, Ogasawara AK, Yang R, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002; 39: 1095-100.
41. Luo J, Xiong Y, Han X, Lu Y. VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications. J Mol Med 2011; 89: 635-45.
42. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-36.
43. Blann AD, Belgore FM, Constans J, Conri C, Lip GY: Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001; 87:1160-3.
44. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GYH. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 2001; 87: 805-7.
45. Felmeden DC, Spencer CGC, Belgore FM, Blann AD, Gareth Beevers D, Lip GYH. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16: 11-20.
46. Nadar SK, Blann AD, Lip GYH. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Internal Med 2004; 256: 331-7.
47. Patel JV, Lim HS, Nadar S, Tayebjee M, Hughes EA, Lip GYH. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 2006; 24: 117-21.
48. Chung NA, Beevers DG, Lip GYH. Effects of losartan vs. hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press 2004; 13: 183-9.
49. Tsai WC, Li YH, Huang YY, Lin CC, Chao TH, Chen JH. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci 2005; 109: 39-43.
50. Nadar SK, Blann A, Beevers DG, Lip GYH. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005; 258: 336-43.
51. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 2003; 9: 1715-32.
52. Felmeden DC, Spencer CGC, Chung NAY, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92: 400-5.
53. Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998; 275: H1054-61.
54. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
55. Nadar SK, Blann A, Lip GYH. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients. Am J Hypertens 2006; 19: 970-7.
56. Ferroni P, Martini F, D'Alessandro R, et al. In vivo platelet activation is responsible for enhanced Vascular Endothelial Growth Factor levels in hypertensive patients. Clin Chim Acta 2008; 388: 33-7.
57. Wei P, Milbauer LC, Enenstein J, Nguyen J, Pan W, Hebbel RP. Differential endothelial cell gene expression by African Americans vs. Caucasian Americans: a possible contribution to health disparity in vascular disease and cancer. BMC Med 2011; 9: 2.
58. Caulfield M, Munroe P, Pembroke J, et al. Genome-wide mapping of human loci for essential hypertension. Lancet 2003; 361: 2118-23.
59. Garcia EA, Newhouse S, Caulfield MJ, Munroe PB. Genes and hypertension. Curr Pharm Des 2003; 9: 1679-89.
60. Samani NJ. Genome scans for hypertension and blood pressure regulation. Am J Hypertens 2003; 16: 167-71.
61. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493-5.
62. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-5.
63. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type II diabetes. Diabetes 2002; 51: 1635-9.
64. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004: 53: 861-4.
65. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant 2007; 22: 827-32.
66. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49: 3611-6.
67. Sandrim VC, Palei AC, Cavalli RC, et al. Vascular endothelial growth factor genotypes and haplotypes are associated with preeclampsia but not with gestational hypertension. Mol Hum Reprod 2009; 15: 115-20.
68. Howell WM, Ali S, Rose-Zerilli MJ, Ye S. VEGF polymorphisms and severity of atherosclerosis. J Med Genet 2005; 42: 485-90.
69. Ayerden Ebinç F, Haksun E, Ulver DB, et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med 2008; 47: 1511-6.
70. Palmirotta R, Ferroni P, Ludovici G, et al. Vascular endothelial growth factor gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clin Biochem 2010; 43: 1090-5.
71. Mohammadi M, Bazrafshani MR, Day PJ, Ollier WE. Vascular Endothelial Growth Factor Production is Regulated by Gene Polymorphisms. Iran J Immunol 2009; 6: 119-29.
72. Szaflik JP, Wysocki T, Kowalski M, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 39-43.
73. Battegay EJ, de Miguel LS, Petrimpol M, Humar R. Effects of antihypertensive drugs on vessel rarefaction. Curr Opin Pharmacol 2007; 7: 151-7.
74. Sobti RC, Maithil N, Thakur H, Sharma Y, Talwar KK. VEGF and IL-4 gene variability and its association with the risk of coronary heart disease in north Indian population Mol Cell Biochem 2010; 341: 139-148.
75. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002; 7: 35-43.
76. Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96: 946-51.
77. Tsioufis C, Dimitriadis K, Andrikou E, et al. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. Am J Kidney Dis 2010; 55: 1050-9.
78. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
79. Advani A, Kelly DJ, Advani SL, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 2007; 104: 14448-53.
80. Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-7.
81. Bortoloso E, Del Prete D, Dalla Vestra M, et al. Quantitative and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol 2004; 150: 799-807.
82. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002; 290: 177-84.
83. Kim NH, Jung HH, Cha DR, Choi DS. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J Endocrinol 2000; 165: 617-24.
84. Cha DR, Kim NH, Yoon JW, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int 2000; 77: S104-12.
85. Kim NH, Kim KB, Kim DL, et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet Med 2004; 21:545-51.
86. Mayer G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 2011; 26: 1132-7.
87. Neusser MA, Lindenmeyer MT, Moll AG, et al. Human nephrosclerosis triggers a hypoxia related glomerulopathy. Am J Pathol 2010; 176: 594-607.
88. Rudnicki M, Perco P, Enrich J, et al. Hypoxia response and VEGFA expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest 2009; 89: 337-46.
89. Katavetin P, Inagi R, Miyata T, et al. Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/ hypoxia-responsive element pathway. Biochem Biophys Res Com 2008; 367: 305-10.
90. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 2010; 56: 463-70.
91. Sharma A, Bettis DI, Cowden JW, Mohan RR. Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo. Mol Vis 2010; 23: 720-8.
92. Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-Iconverting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073-8.
93. Weigel R, Hohenstein A, Schlickum L, Weiss C, Schilling L. Angiotensin converting enzyme inhibition for arterial hypertension reduces the risk of recurrence in patients with chronic subdural hematoma possibly by an antiangiogenic mechanism. Neurosurgery 2007; 61: 788-92.
94. Gao L, Yu DM. Molecular mechanism of limbs' postischemic revascularization improved by perindopril in diabetic rats. Chin Med J (Engl) 2008; 121: 2129-33.
95. Lowenthal DT, Saris SD, Packer J, Haratz A, Conry K. Mechanisms of action and the clinical pharmacology of beta-adrenergic blocking drugs. Am J Med 1984; 77: 119-27.
96. Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vasc Pharmacol 2010; 53: 200-8.
97. Kamp O, Metra M, Bugatti S, et al. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs 2010; 70: 41-56.
98. Sugiura T, Kondo T, Kureishi-Bando Y, et al. Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension 2008; 52: 491-8.
99. Jung HJ, Kim JH, Shim JS, Kwon HJ. A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxiainducible factor. J Biol Chem 2010; 13: 25867-74.
100. Munaron L, Fiorio Pla A. Endothelial calcium machinery and angiogenesis: understanding physiology to interfere with pathology. Curr Med Chem 2009; 16: 4691-703.
101. Otake AH, Mattar AL, Freitas HC, et al. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol 2010; 66: 79-87.
102. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-636.
103. The ARB Trialists Collaboration Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens 2011; 29: 623-35.
104. Petersen MC, Greene AS. Angiotensin II is a critical mediator of prazosin-induced angiogenesis in skeletal muscle. Microcirculation 2007; 14: 583-91.
105. Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 2005; 94: 374-88.
106. Ciccarelli M, Santulli G, Campanile A, et al. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 2008; 153: 936-46.
107. Miura S, Saku K. Regulation of angiogenesis and angiogenic factors by cardiovascular medications. Curr Pharm Des 2007; 13: 2113-7.
108. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927-34.
109. Mourad JJ, Levy BI. Mechanisms of antiangiogenic-induced arterial hypertension. Curr Hypertens Rep 2011; 13: 289-93.
110. Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56: 1131-6.
111. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
112. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
113. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-86.
114. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44.
115. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. The Oncologist 2007; 12: 356-61.
116. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
117. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12: 713-8.
118. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
119. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007; 370: 2103-11.
120. Brahmer JR, Dahlberg SE, Gray RJ, et al. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol 2011; 6: 103-8.
121. Smith IE, Pierga JY, Biganzoli L, et al.; on behalf of the ATHENA Study Group. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2011; 22: 595-602.
122. Stathopoulos GP, Batziou C, Trafalis D, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78: 376-81.
123. Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-smallcell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11: 733-40.
124. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-22.
125. Stadler WM, Figlin RA, McDermott DF, et al.; ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-80.
126. Kozloff M, Yood MU, Berlin J, et al.; Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-70.
127. Goodwin R, Ding K, Seymour L, et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010; 21: 2220-2226.
128. Van Cutsem E, Rivera F, Berry S, et al.; First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-7.
129. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010; 15: 1179-91.
130. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460-8.
131. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010; 66: 813-821.
132. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension. Pathogenesis and management. Biodrugs 2011; 25: 159-69.
133. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Antivascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010; 15: 130-41.
134. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
135. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
136. Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anti-Cancer Drugs 2011; 22: 1-8.
137. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358: 95-7.
138. Kim JJ, Vaziri SAJ, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118: 1946-54.
139. Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract 2011; 816897.
140. Eskens FA, Steeghs N, Verweij J, et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol 2009; 27: 4169-76.
141. Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14: 3470-6.
142. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2011; 77: 163-71.
143. Roden DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004; 350: 1013-22, 2004.
144. Mir O, Coriat R, Ropert S, et al. Treatment of bevacizumabinduced hypertension by amlodipine. Invest New Drugs 2012; 30: 702-7.
145. Bottiglieri S, Muluneh B, Sutphin S, Iacovelli L, Adams V. Blood pressure control in patients receiving bevacizumab in an outpatient cancer center. J Oncol Pharm Pract 2011; 17: 333-8.
146. Maitland ML, Bakris GL, Black HR, et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.
147. Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010; 29: 95.
148. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa vs. interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-43.
149. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28: 949-54.
150. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10:151-6.
151. Cancer Therapy Evaluation Program (2003) Common Terminology Criteria for Adverse Events, V3.0, DCTD, NCI, NIH, DHHs. http://ctep.cancer.gov/.
152. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-72.
153. Langenberg MH, van Harpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 2009; 27: 6152-9.
154. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124:1687-91.
155. Khakoo AY, Sidman RL, Pasqualini R, et al. Does the reninangiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008; 68:9112-5.
156. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.